Transportability to the European population of Efficacy of Belumosudil as Compared with Physician’s Choice of Best Available Therapy for The Treatment of Chronic Graft Versus Host Disease

In line with positive efficacy results observed in previous real-world evidence studies in US and European patients, findings from this transportability analysis indicate that the treatment-response pattern are similar in Europe compared to US and cGVHD patients treated with belumosudil would have significantly more clinical benefit compared to BAT in Europe.